• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Intra-Cellular Ther (NQ: ITCI )

    74.94 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 356
    Open 74.94
    Bid (Size) 29.98 (2)
    Ask (Size) 89.20 (1)
    Prev. Close 74.94
    Today's Range 74.94 - 74.94
    52wk Range 45.50 - 84.89
    Shares Outstanding 94,324,313
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
    Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%). 
    Via Benzinga
    Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
    Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
    Via Investor's Business Daily

    Performance

    YTD
    +6.31%
    +6.31%
    1 Month
    -0.72%
    -0.72%
    3 Month
    +4.08%
    +4.08%
    6 Month
    +15.04%
    +15.04%
    1 Year
    +18.88%
    +18.88%

    More News

    Read More
    Patterson Companies, Silk Road Medical, Micron, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
    Via Benzinga
    Exposures Product Safety
    Where Intra-Cellular Therapies Stands With Analysts
    Via Benzinga
    Analyst Ratings For Intra-Cellular Therapies
    Via Benzinga
    The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
    Via Benzinga
    Intra-Cellular Therapies Eyes $1.7 Billion Opportunity After Phase 3 Win
    Via Investor's Business Daily
    The Secret Stock Stash: 3 Overlooked Picks That Belong in Every Portfolio
    Via InvestorPlace
    ITCI Stock Earnings: Intra-Cellular Therapies Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    3 Biotech Stocks With Skyrocketing Potential: April 2024
    Via InvestorPlace
    Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    How Is The Market Feeling About Intra-Cellular Therapies?
    Via Benzinga
    8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
    Via Benzinga
    Where Intra-Cellular Therapies Stands With Analysts
    Via Benzinga
    Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
    Via Benzinga
    Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study
    Via Benzinga
    UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Climbs to New 52-Week High
    Via Investor Brand Network
    Intra-Cellular Therapies Stock Launches 20% Into Breakout Territory On Depression Test Results
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
    Via InvestorPlace
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.